Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACTINIUM PHARMACEUTICALS, INC.

(ATNM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Actinium Pharmaceuticals : HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $57 From $65, Maintains Buy Rating

04/01/2021 | 11:03am EDT


ę MT Newswires 2021
All news about ACTINIUM PHARMACEUTICALS, INC.
09:02aACTINIUM PHARMACEUTICALS STOCK JUMPS : Atnm)
AQ
09/16ACTINIUM PHARMACEUTICALS : Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iom..
AQ
09/15ACTINIUM PHARMACEUTICALS : Completes Enrollment in Phase 3 Trial of Iomab-B to Treat Leuke..
MT
09/15Actinium Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 SIERRA Trial..
CI
08/03ACTINIUM PHARMACEUTICALS : HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to..
MT
07/30ACTINIUM PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
AQ
07/30Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended Ju..
CI
06/29ACTINIUM PHARMACEUTICALS : Announces Inclusion in Russell Microcap Index
AQ
06/17ACTINIUM PHARMACEUTICALS : Awarded Patents in Europe, Japan for Antibody Radiation Conjuga..
MT
06/15Actinium Pharmaceuticals, Inc. Announces Safety Data from Phase 3 SIERRA Trial of Iomab..
CI
More news
Analyst Recommendations on ACTINIUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 1,02 M - -
Net income 2021 -22,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,85x
Yield 2021 -
Capitalization 173 M 173 M -
Capi. / Sales 2021 170x
Capi. / Sales 2022 11,2x
Nbr of Employees 32
Free-Float 98,5%
Chart ACTINIUM PHARMACEUTICALS, INC.
Duration : Period :
Actinium Pharmaceuticals, Inc. Technical Analysis Chart | ATNM | US00507W2061 | MarketScreener
Technical analysis trends ACTINIUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 7,40 $
Average target price 30,00 $
Spread / Average Target 305%
EPS Revisions
Managers and Directors
Sandesh Seth Chairman & Chief Executive Officer
Steve O'Loughlin Chief Financial Officer
Mark S. Berger Chief Medical Officer
Dale L. Ludwig Chief Scientific & Technology Officer
Avinash Desai Executive VP-Clinical Development & Operations
Sector and Competitors
1st jan.Capi. (M$)
ACTINIUM PHARMACEUTICALS, INC.0.38%158
GILEAD SCIENCES, INC.21.80%88 970
BIONTECH SE315.86%81 878
WUXI APPTEC CO., LTD.35.75%69 413
REGENERON PHARMACEUTICALS32.66%66 632
VERTEX PHARMACEUTICALS-21.44%48 168